linjc16/ctgov huggingface dataset:
Secondary Mentoring Program Evaluation

Study Overview
=================
Brief Summary
-----------------
Mentorship is essential to job satisfaction and promotion among academic physicians, and literature suggests that a single mentor is rarely sufficient. The investigators are studying whether implementation of a secondary mentorship program among physicians at their institution leads to improved job satisfaction over 6 months.

Official Title
-----------------
Department of Medicine Secondary Mentoring Program Evaluation

Conditions
-----------------
Satisfaction

Intervention / Treatment
-----------------
* Other: Secondary Mentor
* Other: Career Development Resources


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physician employed as full-time faculty in the Massachusetts General Hospital Department of Medicine. Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Secondary Mentor Plus Career Development Resources<br>Subjects will be assigned a secondary mentor for 6 months. Subjects will also receive career development resources. | Other: Secondary Mentor<br>* Subjects will be matched with a secondary mentor from the Department of Medicine for 6 months. Mentors and mentees are expected to hold one-on-one meetings monthly for the first 3 months followed by at least once every 3 months thereafter.<br>Other: Career Development Resources<br>* Subjects will receive career development resources.<br>|
| Other: Career Development Resources Alone<br>Subjects will not be assigned a secondary mentor. Subjects will receive career development resources only. | Other: Career Development Resources<br>* Subjects will receive career development resources.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Job satisfaction | Job satisfaction is measured by the following question on a questionnaire developed by the investigators: Overall how satisfied are you with your current position? Responses are on a 5-point Likert scale (very unsatisfied, unsatisfied, neither, satisfied, very satisfied). | 6 months |
EXPert System, ALImentary

Study Overview
=================
Brief Summary
-----------------
Eating disorders (ED) are often undetected in the general population resulting in delayed treatment. The SCOFF questionnaire has been validated for eating disorders screening in primary care, but does not identify the type of eating disorder. Objective: Investigators evaluated the performance of a clinical algorithm (ExpaliTM) combining answers to SCOFF questionnaire with Body Mass Index (BMI) to identify four Broad Categories of ED derived from DSM-5. Design: Clinical algorithm (ExpaliTM) was developped from 104 combinations of BMI levels and answers to five SCOFF questions. Two senior ED specialists allocated each combination to one of the four Broad Categories of ED (DSM-5 diagnostics): restrictive disorder (anorexia nervosa typical, atypical and restrictive food intake disorders), bulimic disorder (typical and with low frequency or duration), hyperphagic disorder (binge eating disorders typical and with low frequency or duration) and other specified ED. The performance of ExpaliTM was evaluated on data from patients referred to the Nutrition Department including a precise DSM-5 diagnosis of ED, a positive SCOFF test (at least 2 yes answers) and BMI. Sensitivity, specificity values with a 95% confidence interval (95% CI) and Youden index were calculated for each category.

Official Title
-----------------
Screening and Diagnosis Help of Eating Disorders

Conditions
-----------------
Eating Disorder Symptom

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: eating disorders SCOFF test = 2 or more Exclusion Criteria: no eating disorders SCOFF test = 0 or 1

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensivity and specificity of the clinical algorithm |  | inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bulimia, anorexia
Dacron vs Dardik for Fem-Pop Bypass

Study Overview
=================
Brief Summary
-----------------
Clinical trial for the comparison of long-term patency of heparin-bonded Dacron and human umbilical vein vascular prostheses in above-knee femoro-popliteal bypass surgery.

Official Title
-----------------
Heparin Bonded and Collagen Coated Polyester or Human Umbilical Vein for Femoropopliteal Bypass: a Prospective Randomised Multicentre Trial.

Conditions
-----------------
Intermittent Claudication, Arterial Occlusive Diseases, Atheroslerosis

Intervention / Treatment
-----------------
* Device: heparin-bonded and collagen coated polyster
* Device: Human umbilical vein femoro-popliteal bypass


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 31 to 89 intermittent claudication ABI below 0.8 Exclusion Criteria: non elective surgery life expectancy below 2 yrs contraindication for anticoagulant therapy

Ages Eligible for Study
-----------------
Minimum Age: 31 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Dacron<br>Patients receiving polyester above-knee femoro-popliteal bypass | Device: heparin-bonded and collagen coated polyster<br>* femoro-popliteal bypass<br>|
| Active Comparator: HUV<br>patients receiving HUV femoro-popliteal bypass | Device: Human umbilical vein femoro-popliteal bypass<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary and primary-assisted bypass patency |  | 1 - 5 yrs | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary bypass patency |  | 1 - 5 yrs |
Gender Differences in Parkinsonian Patients- a Swedish Register Study

Study Overview
=================
Brief Summary
-----------------
BACKGROUND: The complex impact of gender has been studied in different perspectives of health and disease in the literature. However, few attempts have been made to compile data from systematic disease specific registrations Swedish National Quality Registers play an important role in collecting large amounts of diagnose specific data, symptoms, and treatments. The subset Parkinson Registry has been in use for more than 20 years and are represented in all counties and hospitals where neurological care is provided in Sweden and offer optimal conditions to describe gender specific differences in the use of diagnostic tools, lead times and symptom profiles.

Detailed Description
-----------------
Aim: To study differences between gender in diagnostic tools, pharmacological interventions, and self-reported symptoms in Parkinson´s Disease (PD). METHODS: Data were extracted from the Swedish Neuro Registers, one of the Swedish National Quality Registers. A mix of urban and rural parts of the country were chosen and data were divided by gender. Self-reported first experienced PD related symptom was used to define the starting point when processing the data. Zero to three years from this point was defined as early symptoms and over three years as late symptoms. CONCLUSION: Differences between gender were seen in all chosen aspects, both diagnostically. Distinctions were also prominent in reported NonMotorSymptoms (NMS) profiles. These findings should be important to take into consideration for patients, professional staff, and caregivers in the daily work with gender mixed PD groups.

Official Title
-----------------
Gender Differences in Diagnostic Tools, Medication, Time to Medication and Non-motor Symptoms in Parkinsonian Patients- a Swedish Register Study

Conditions
-----------------
Parkinson Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants registered in the Swedish Neuro Registers. Parkinson´s Disease Acceptance of extraction of data Exclusion Criteria: non parkinsonian patients Participants in the Registries who have not given allowance of extraction of data.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants in the Swedish Neuro Register<br>Participants are patients with parkinsonian symptoms | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences between gender | investigations, medications,NonMotorSymptoms | 2006-2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NonMotorSymptoms, medication, National Registries
Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Oceania and North America. The aim of this trial is to assess the long term safety and efficacy of biphasic insulin aspart 30 in subjects with type 2 diabetes who have completed the BIAsp-1234 trial.

Official Title
-----------------
An Open Label, Non Comparative, Multicentre Extension Trial to Assess the Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Who Have Completed BIAsp-1234

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: biphasic insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must have been correctly included in and completed BIAsp-1234 Exclusion Criteria: Persistent non-compliance with study medication, visit schedules or other trial specific procedures during the preceding trial Fulfilment of any withdrawal criteria prior to and including the final visit of the BIAsp-1234. Females only: breast feeding, intention of becoming pregnant, or judged to be using inadequate contraceptive measures (adequate contraceptive methods are sterilisation,IUD (Intra Uterine Device), oral contraceptives or barrier methods) Known or suspected allergy to trial product or related products Development since entry into the previous trial of late diabetic micro or macro vascular complications, which in the opinion of the Investigator indicates a progressed state of disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Drug: biphasic insulin aspart<br>* Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of adverse events |  |  | 
| Frequency of hypoglycaemic episodes |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c (glycosylated haemoglobin) |  |  |
The Effect of Sleeve Gastrectomy on Food Preference

Study Overview
=================
Brief Summary
-----------------
This is a questionnaire asking about the sleeve gastrectomy surgery and how has it altered food preferences before and after surgery.

Detailed Description
-----------------
Participants that will undergo the sleeve gastrectomy surgery by Dr. Drake Bellanger's, will be asked to participant in a questionnaire survey. Once given the consent to participate, a food preference questionnaire (FPQ) will be administered at a pre-operative visit and then a six-week follow up visit at Dr. Drake Bellanger's office.

Official Title
-----------------
The Effect of Sleeve Gastrectomy on Food Preference

Conditions
-----------------
Severe Obesity

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female, 18 years or over, who will undergo a sleeve gastrectomy for obesity by Dr. Drake Bellanger. Exclusion Criteria: Women who are pregnant or nursing.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sleeve gastrectomy surgery Participants<br>Male or female who will undergo a sleeve gastrectomy for obesity by Dr. Drake Bellanger. | Other: Questionnaire<br>* Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.<br>* Other names: Food Preference questionnaire (FPQ);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participants food preferences before sleeve gastrectomy surgery and after surgery. | A list of food items are on a questionnaire asking food preferences, Breads, Cereals, Grain products, Fruits and Juices, Fats and oils, Milk, etc. which allows the subjects to select their food preferences before and after the surgery. | Change from Baseline in preferences after follow-up six weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participants weight change before sleeve gastrectomy surgery and after surgery focusing on specific macronutrient. | A participant is weighted at baseline visit and follow-up visit 6 weeks after the surgery. | Change from Baseline in weight after follow-up six weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastrectomy
Assessing Endoloop-assisted Polypectomy in Patients With Antiplatelet Therapy

Study Overview
=================
Brief Summary
-----------------
The aims of this study were to examine: 1) safety and feasibility of antiplatelet therapy interruption 7 days prior to polypectomy in patients with long-term antiplatelet therapy; 2) safety and feasibility of endoloop assisted snare polypectomy in patients with long-term antiplatelet therapy; 3) safety and feasibility of so called ligate and let go approach in patients with long-term antiplatelet therapy.

Official Title
-----------------
Endoloop-assisted Colorectal Polypectomy or Ligate and Let go in Patients With Long-term Antiplatelet Therapy

Conditions
-----------------
Colorectal Polyp

Intervention / Treatment
-----------------
* Procedure: Endoloop-assisted ligate and let go colorectal polypectomy
* Procedure: Endoloop-assisted snare colorectal polypectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pedunculated colorectal polyps larger than 2cm in diameter long-term antiplatelet therapy Exclusion Criteria: presence of intraepithelial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ligate and let go<br>Subjects are submitted to endoloop-assisted ligate and let go colorectal polypectomy. | Procedure: Endoloop-assisted ligate and let go colorectal polypectomy<br>* The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.<br>|
| Active Comparator: Snare polypectomy<br>Subjects are submitted to endoloop-assisted snare colorectal polypectomy | Procedure: Endoloop-assisted snare colorectal polypectomy<br>* The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-polypectomy bleeding |  | 24h-15 days |
Suggamadex and Fast-track Cardiac Anesthesia in a Developing Country

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to retrospectively review our preliminary experience during a surgical trip to Tuxtla, Mexico, using suggamadex to reverse neuromuscular blockade following CPB and cardiac surgery for repair of CHD in infants and children.

Official Title
-----------------
Retrospective Chart Review of Fast-track Cardiac Anesthesia Using Suggamadex for Rapid Reversal of Neuromuscular Blockade Following Cardiac Surgery in a Developing Country

Conditions
-----------------
Suggamadex, Surgery for Congenital Heart Disease

Intervention / Treatment
-----------------
* Procedure: Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent cardiac surgery and cardiopulmonary bypass in Tuxtla, Mexico in September 2015. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sugammadex group<br>sugammadex to reverse neuromuscular blockade following cardiac surgery | Procedure: Surgery<br>* Sugammadex to reverse neuromuscular blockade<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical effects of the reversal of neuromuscular blockade with suggamadex following surgery for congenital heart disease in infants and children |  | After cardiac surgery, on average within 5 minutes |
ATAC - Bone Density Sub-Protocol

Study Overview
=================
Brief Summary
-----------------
To assess and quantify the changes in bone mineral density between the ARIMIDEX and ARIMIDEX plus NOLVADEX groups when compared to the NOLVADEX alone treatment group whilst receiving trial therapy.

Official Title
-----------------
A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Metabolism of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, (in Comparison to a Control Group) When Used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women

Conditions
-----------------
Bone Density

Intervention / Treatment
-----------------
* Drug: Anastrozole
* Drug: Tamoxifen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible for entry into the main ATAC trial 1033IL/0029 Women defined as post-menopausal Patients with histologically proven operable invasive breast cancer Who following primary surgery have a good prognosis and would be ethically suitable to remain untreated Exclusion Criteria: Excluded from entry into the main ATAC trial (1033IL/0029) Patients who have received hormone replacement therapy within the previous 12 months prior to randomisation Patients who have received bisphosphonate therapy within the previous 12 months prior to randomisation Patients who have had a bone fracture within the previous 6 months prior to randomisation

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Arimidex 1mg + Nolvadex placebo | Drug: Anastrozole<br>* 1mg, orally, once daily<br>* Other names: Arimidex;|
| Active Comparator: 2<br>Arimidex placebo + Nolvadex 20mg | Drug: Anastrozole<br>* 1mg, orally, once daily<br>* Other names: Arimidex;Drug: Tamoxifen<br>* 20mg, orally, once daily<br>* Other names: Nolvadex;|
| Active Comparator: 3<br>Arimidex 1mg + Nolvadex 20mg | Drug: Tamoxifen<br>* 20mg, orally, once daily<br>* Other names: Nolvadex;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to withdrawal |  |  | 
| Time to recurrence |  |  |